Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients

Transplantation

Volumn 92, Issue 2, 2011, Pages 217-223

  Myhre, Hans Arne ^a,b   Haug Dorenberg, Dagny ^a   Kristiansen, Knut Ivan ^a   Rollag, Halvor ^a,c   Leivestad, Torbjørn ^a   Åsberg, Anders ^d   Hartmann, Anders ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Section of Nephrology   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Cytomegalovirus; Cytomegalovirus infection; Ganciclovir resistance; Preemptive; Viral kinetics

Indexed keywords

CALCINEURIN INHIBITOR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALGANCICLOVIR;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG SAFETY; ERADICATION THERAPY; FEMALE; GENE MUTATION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; UL54 GENE; UL97 GENE; VIREMIA; VIRUS GENE; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOSCARNET; GANCICLOVIR; HUMANS; INCIDENCE; INFANT; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; NORWAY; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RETROSPECTIVE STUDIES; TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960309676     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821fad25     Document Type: Article

References (23)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. NEngl JMed 1998; 338: 1741.
2. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811.
3. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valgan-ciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495.
4. Åsberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106.
5. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ Transplantation. Transplantation 2010; 89: 779.
6. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356:645.
7. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35: 886.
8. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49: 873.
9. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Che-mother 2010; 54:2371.
10. Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cyto-megalovirus in the era of valganciclovir prophylaxis: Therapeutic im-plication and outcomes. Clin Transplant 2008; 22: 162.
11. Van der Beek MT, Berger SP, Vossen A, et al. Pre-emptive versus se-quential prophylactic-pre-emptive treatment regimens for cytomega-lovirus in renal transplantation: Comparison oftreatment failure and antiviral resistance. Transplantation 2010; 89: 320.
12. Singh N, Wannstedt C, Keyes L, et al. Valganciclovir as pre-emptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients ofcytomegalovirus-seropositive donor allografts. Liver Transpl 2008; 14: 240.
13. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus- resistance mutation after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. JInfect Dis 2004; 189: 1615.
14. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83.
15. Singh N. Preemptive therapy versus universal prophylaxis with ganci-clovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32: 742.
16. Limaye AP, Raghu G, Koelle DM, et al. High incidence ofganciclovir- resistant cytomegalovirus infection among lung transplant recipients receiving Preemptive therapy.JInfec Dis 2002; 185: 20.
17. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell re-sponses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29.
18. Hadaya K, Wunderli W, Deffernez C, et al. Monitoring ofcytomegalo-virus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol 2003; 41: 3757.
19. Chou S. Cytomegalovirus UL 97 mutations in the era ofganciclovir and maribavir. Rev Med Virol 2008; 18: 233.
20. Iwasenko JM, Scott GM, Rawlinson WD, et al. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J Med Virol 2009; 81: 507.
21. Sagedal S, Nordal PN, Hartmann A, et al. Preemptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganci-clovir: A randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899.
22. Rollag H, Sagedal S, Kristiansen KI, et al. Cytomegalovirus DNA con-centration in plasma predicts development of cytomegalovirus disease in kidneytransplant recipients. Clin Microbiol Infect 2002; 8: 431.
23. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society ofTransplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report.Am JTransplant 2005; 5: 218.